Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar Q2 revenue falls 4% to $174.4 million; GAAP EPS $0.64 vs $0.73

Negative Impact 3 of 5 earnings Written later

Amphastar reported second-quarter 2025 results on August 7, 2025. Net revenues fell 4% to $174.4 million, and GAAP net income declined to $31.0 million, or $0.64 per diluted share, from $0.73 a year earlier. Growth in BAQSIMI sales was offset by lower glucagon and epinephrine sales, and the board increased its share buyback program by $50 million.

Key points

  • Net revenues were $174.4 million versus $182.4 million a year earlier, down 4%.
  • GAAP diluted EPS was $0.64 versus $0.73; adjusted non-GAAP diluted EPS was $0.85 versus $0.94.
  • BAQSIMI product revenues rose 51% to $46.7 million; epinephrine revenues fell 42% and glucagon fell 25%.
  • On August 5, 2025, the board authorized a $50 million increase to the share buyback program.

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECAug 7, 2025, 4:31 PM ET
Accession number0001297184-25-000048

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.